Horizon Provides Assurances That Tepezza Sales Are Set To Soar
Guidance Maintained For 30% Growth In 2022
Executive Summary
Sales of the thyroid eye disease drug were impacted by surging COVID-19 case numbers in the first quarter, but the company is expanding its commercial team to capitalize on new TED market insights.
You may also be interested in...
Horizon's Revised TED Indication Should Help Tepezza
With Tepezza now clearly labeled for all thyroid eye disease patients, rather than just acute cases, Amgen can be more optimistic about economics around of its Horizon acquisition, analysts suggest.
TED Talk: Viridian’s Early Data Indicate Strong Competitor To Horizon’s Tepezza
Viridian says Phase I/II data for its thyroid eye disease candidate outperforms Horizon’s Tepezza on multiple measures. Company plans quick advancement into Phase III for VRDN-001.
Horizon Will Submit Krystexxa sBLA To Strengthen Clinical Profile In Gout
A clinical trial confimred Krystexxa in combination with methotrexate increased response rates in patients with uncontrolled gout.